Recombinant Human RECK Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10309-RE

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10309-RE-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

O95980

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all RECK Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human RECK protein
Human RECK
(Met1-Pro941)
Accession # O95980		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Gly27

Predicted Molecular Mass

127 kDa

SDS-PAGE

125-137 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human RECK Fc Chimera (Catalog # 10309-RE) is immobilized at 2 µg/mL (100 µL/well), Recombinant Human TEM5/GPR124 His-tag (Catalog # 10206-TE) binds with an ED50 of 0.7-5.6 μg/mL.

Scientific Data Images for Recombinant Human RECK Fc Chimera Protein, CF

Recombinant Human RECK Fc Chimera Protein Binding Activity

Recombinant Human RECK Fc Chimera Protein Binding Activity

When Recombinant Human RECK Fc Chimera (Catalog # 10309-RE) is immobilized at 2 µg/mL (100 µL/well), Recombinant Human TEM5/GPR124 His-tag (Catalog # 10206-TE) binds with an ED50 of 0.7-5.6 µg/mL.
Recombinant Human RECK Fc Chimera Protein SDS-PAGE

Recombinant Human RECK Fc Chimera Protein SDS-PAGE

2 μg/lane of Recombinant Human RECK Fc Chimera (Catalog # 10309-RE) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing a band under reducing conditions at ~131 kDa.

Formulation, Preparation and Storage

10309-RE
Formulation Lyophilized from a 0.2 μm filtered solution in Tris and NaCl.
Reconstitution Reconstitute at 500 μg/mL in water.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: RECK

Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), also known as Suppressor of tumorigenicity 15 protein (ST15), is a 971 amino acid highly conserved protein that serves as an important mediator of tissue remodeling (1). The multi-domain protein includes hydrophobic regions at the N- and C-termini that correspond to a signal domain and GPI anchoring site, respectively (2). Internally, there are three serine protease inhibitor-like (SPI) domains and two regions with EGF-like repeats (2). The N-terminal region also contains a cysteine-rich domain essential for MMP (3) and Wnt7 binding (4, 5). RECK is normally expressed in all human and mammalian cells (2, 6) while undetectable or downregulated in malignant and cancer cells (1, 2). There is a strong correlation between expression of RECK and prognosis making it a prognostic marker target in several cancers including colorectal, breast, and pancreatic (1, 3, 7-9). Polymorphisms in RECK leads to increased cancer susceptibility (10). RECK's ability to bind several proteins confers complex functionality. RECK is known to bind and inhibit MMPs (1, 2, 11), interact with ADAMTS10 (12), modulate Notch signaling (13), promote p53 signaling (14) and act as a selective Wnt7 receptor through binding of Gpr124 (4). RECK acts as a tumor suppression gene by inhibiting angiogenesis, invasion, and metastasis through its role in the regulation and signaling within the extracellular matrix (1, 3, 6). Through its interaction with Wnt7, RECK promotes angiogenesis and regulates the blood-brain barrier in CNS by mediating canonical Wnt/beta-catenin signaling (4).

References

  1. Alexius-Lindgren, M. et al. (2014) Anticancer Res. 34:3867.
  2. Takahashi, C. et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95:13221.
  3. Clark, J.C.M. et al. (2007) Cancer Mestast. Rev. 26:675.
  4. Vallon, M. et al. (2018) Cell Reports. 25:339.
  5. Cho, C. et al. (2019) Elife. 8:e47300.
  6. Oh, J. et al. (2001) Cell. 107:789.
  7. Takeuchi, T. et al. (2004) Clin. Cancer Res. 10:5572.
  8. Zhang, G. et al. (2012) Cancer Sci. 103:1084.
  9. Masui, T. et al. (2003) Clin. Cancer Res. 9:1779.
  10. Chung, T.T. et al. (2012) PLoS ONE. 7:e33517.
  11. Miki, T. et al. (2007) J. Biol. Chem. 282:12341.
  12. Matsuzaki, T. et al. (2018) Biol. Open 7:bio033985.
  13. Muraguchi, T. et al. (2007) Nat. Neurosci. 10:838.
  14. Liu, Y. et al. (2018) J. Cell. Biochem. 119:3058.

Long Name

Reversion-inducing-cysteine-rich Protein with Kazal Motifs

Alternate Names

ST15

Entrez Gene IDs

8434 (Human); 53614 (Mouse)

Gene Symbol

RECK

UniProt

O95980

Additional RECK Products

Product Documents for Recombinant Human RECK Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human RECK Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.